Celldex Therapeutics, Inc.
Investor Relations Department
119 Fourth Avenue
Needham, MA 02494-2725
United States

Visit IR website
Sign-up for email alerts

NASDAQ: CLDX [1]	
Last Trade:	3.24
Trade Time:	4:00 PM ET Mar 22, 2017
Change:	0.07 (2.208%)
Day Range	3.05 - 3.25
52-Week Range	2.85 - 5.13
Volume	2,682,518
Market Cap. ($M)	399.200
Shares Out (M)	123.210

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

… (more)

Stock Performance

Press Releases [View all]

Mar 14, 2017
Celldex Provides Corporate Update and Reports Full Year 2016 Results

Mar 1, 2017
Celldex Therapeutics Announces Appointment to Board of Directors

Feb 13, 2017
Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call

Dec 14, 2016
Celldex Therapeutics Announces Appointment to Board of Directors

Dec 5, 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Fourth Quarter Financial Results

Mar 14, 2017
Annual Report (10-K)

Apr 21, 2016
Definitive Proxy Statement

Nov 7, 2016
Quarterly Report (10-Q)

Aug 8, 2016
Quarterly Report (10-Q)

May 5, 2016
Quarterly Report (10-Q)

Nasdaq